Last reviewed · How we verify
HPV Vaccinations
At a glance
| Generic name | HPV Vaccinations |
|---|---|
| Also known as | Ceravix |
| Sponsor | UbiVac |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Developing a First-void Urine-based Infection Model to Study HPV-specific Antibody-virion Interaction Before and After HPV Vaccination (PHASE2)
- A Randomized Trial of Digital Interventions to Increase HPV Vaccination Intentions Among Nigerian Caregivers (NA)
- The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Health Beliefs, and Vaccination Behavior Intentions (NA)
- Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (PHASE1)
- Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PHASE4)
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines (PHASE4)
- PREVENT Pilot HPV - Related Cancers Trial (NA)
- Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPV Vaccinations CI brief — competitive landscape report
- HPV Vaccinations updates RSS · CI watch RSS
- UbiVac portfolio CI